Metabolic classification of bladder cancer based on multi-omics integrated analysis to predict patient prognosis and treatment response

[1] Alifrangis C(2019)Molecular and histopathology directed therapy for advanced bladder cancer Nat Rev Urol 16 465-483

[2] McGovern U(2017)Bladder cancer incidence and mortality: A global overview and recent trends Eur Urol 71 96-108

[3] Freeman A(2017)Bladder cancer: Present and future Med Clin (Barc) 149 449-455

[4] Powles T(2017)Landmarks in the treatment of muscle-invasive bladder cancer Nat Rev Urol 14 565-574

[5] Linch M(2017)Comprehensive molecular characterization of muscle-invasive bladder cancer Cell 171 540-556 e525

[6] Antoni S(2016)Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial Lancet 387 1909-1920

[7] Ferlay J(2016)Nivolumab monotherapy in recurrent metastatic urothelial carcinoma (CheckMate 032): a multicentre, open-label, two-stage, multi-arm, phase 1/2 trial Lancet Oncol 17 1590-1598

[8] Soerjomataram I(2004)Metabolic profiles of cancer cells Nat Rev Cancer 4 551-561

[9] Znaor A(2016)Metabolic phenotype of bladder cancer Cancer Treat Rev 45 46-57

[10] Jemal A(2012)A molecular taxonomy for urothelial carcinoma Clin Cancer Res 18 3377-3386

[1] Alifrangis C(2019)Molecular and histopathology directed therapy for advanced bladder cancer Nat Rev Urol 16 465-483

[2] McGovern U(2017)Bladder cancer incidence and mortality: A global overview and recent trends Eur Urol 71 96-108

[3] Freeman A(2017)Bladder cancer: Present and future Med Clin (Barc) 149 449-455

[4] Powles T(2017)Landmarks in the treatment of muscle-invasive bladder cancer Nat Rev Urol 14 565-574

[5] Linch M(2017)Comprehensive molecular characterization of muscle-invasive bladder cancer Cell 171 540-556 e525

[6] Antoni S(2016)Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial Lancet 387 1909-1920

[7] Ferlay J(2016)Nivolumab monotherapy in recurrent metastatic urothelial carcinoma (CheckMate 032): a multicentre, open-label, two-stage, multi-arm, phase 1/2 trial Lancet Oncol 17 1590-1598

[8] Soerjomataram I(2004)Metabolic profiles of cancer cells Nat Rev Cancer 4 551-561

[9] Znaor A(2016)Metabolic phenotype of bladder cancer Cancer Treat Rev 45 46-57

[10] Jemal A(2012)A molecular taxonomy for urothelial carcinoma Clin Cancer Res 18 3377-3386